drugset
drugset / Trial / NCT05546866

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

NCT05546866 ↗

Phase 2 Active not recruiting 51 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, multi-centre, single-arm study assessing the efficacy and safety of osimertinib as adjuvant treatment in stage IB-IIIB (8th AJCC) NSCLC with uncommon EGFRm after receiving complete surgical resection with or without adjuvant chemotherapy.

Timeline

Start
2023-02-09
Primary completion
2029-06-30
Completion
2029-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Osimertinib Small molecule 80 mg Oral

Indications

non-small cell lung carcinoma